Factor VIII deficiency+1
Not recruitingA study looking at the safety of switching from emicizumab to denecimig in adults and adolescents with haemophilia A with or without inhibitors
A study looking at the safety of switching from emicizumab to denecimig in adults and adolescents with haemophilia A with or without inhibitors
- Disease:Factor VIII deficiencyHaemophilia A with anti factor VIII
- Substances:Denecimig
Belgium- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Denecimig
- Sponsor:Novo Nordisk A/S













